Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

81.64 -2.25 (-2.68%)
Official Closing Price Updated: 4:10 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Edwards Lifesciences

< Previous 1 2 3 4 5 6 Next >
News headline image
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Edwards Lifesciences Reports Fourth Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Comments on JenaValve Acquisition
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
AI Diagnostics: The End of the High-Cost Imaging Era
Issued on behalf of VentriPoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
FDA Approves Edwards Lifesciences' SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences Announces CFO Transition Plan
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences Reports Third Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EW Investor News: Rosen Law Firm Investigates Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EW Investor News: If You Have Suffered Losses in Edwards Lifesciences Corporation (NYSE: EW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW
From Rosen Law Firm
Via Business Wire
News headline image
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
Edwards Lifesciences Announces $500 Million Accelerated Share Repurchase
From Edwards Lifesciences Corporation
Via Business Wire
News headline image
EDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Edwards Lifesciences Comments on FTC’s Action to Block Proposed Acquisition of JenaValve
From Edwards Lifesciences Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.